Literature DB >> 3774231

Effects of aging and cholinergic deafferentation on putative muscarinic cholinergic receptor subtypes in rat cerebral cortex.

A B Norman, S N Blaker, L Thal, I Creese.   

Abstract

Despite a 34% decrease in the activity of choline acetyltransferase (ChAT) in the rat cerebral cortex following lesions of the nucleus basalis, there were no changes in the Bmax of the antagonist ligands [3H]quinuclidinyl benzilate ((-)-[3H]QNB) or (-)-[3H]N-methylscopolamine ((-)-[3H]NMS). Furthermore, this treatment produced no significant change in the proportions or affinities of muscarinic receptors having high and low affinity for pirenzepine or (-)-NMS. These data indicate that putative M2 muscarinic receptors are not restricted to ChAT-containing neurons in rat cerebral cortex. In senescent compared to mature rats there was no significant loss of ChAT activity although a significant reduction in the Bmax of both (-)-[3H]QNB and (-)-[3H]NMS binding was observed. However, no changes in the competition of pirenzepine or (-)-NMS for the remaining (-)-[3H]QNB binding sites were observed. Therefore, there is no evidence for any differential regulation of either putative muscarinic receptor subtype in response to cholinergic deafferentation or as a function of the natural aging process.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3774231     DOI: 10.1016/0304-3940(86)90479-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Age-dependent decrease in the affinity of muscarinic M1 receptors in neocortex of rhesus monkeys.

Authors:  M G Vannucchi; P S Goldman-Rakic
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

2.  Effects of aging on the interaction of quinuclidinyl benzilate, N-methylscopolamine, pirenzepine, and gallamine with brain muscarinic receptors.

Authors:  W Surichamorn; O N Kim; N H Lee; W S Lai; E E el-Fakahany
Journal:  Neurochem Res       Date:  1988-12       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.